Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Francesca Galvani
Institution:
University of California, Irvine
Observed institutions:
University of Parma,
University of California, Irvine
ORCID:
0000-0002-7543-9945
Observed ORCID:
0000-0002-7543-9945
OpenAlex ID:
A5056263033
Mechanistic Modeling of Lys745 Sulfonylation in EGFR C797S Reveals Chemical Determinants for Inhibitor Activity and Discriminates Reversible from Irreversible Agents
2023
·
Kemel Arafet
, Laura Scalvini
, et al.
·
Journal of Chemical Information and Modeling
·
26
PDF
Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases
2024
·
Francesca Galvani
, Mariarosaria Cammarota
, et al.
·
Journal of Pineal Research
·
25
PDF
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines
2024
·
Kamal Eltayeb
, Roberta Alfieri
, et al.
·
Biochemical Pharmacology
·
20
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models
2024
·
Silvia La Monica
, Federica Vacondio
, et al.
·
Scientific Reports
·
19
PDF
Development of potent and selective FAAH inhibitors with improved drug-like properties as potential tools to treat neuroinflammatory conditions
2022
·
Alessandro Papa
, Silvia Pasquini
, et al.
·
European Journal of Medicinal Chemistry
·
17
PDF
Unbinding Kinetics of Muscarinic M3 Receptor Antagonists Explained by Metadynamics Simulations
2023
·
Francesca Galvani
, Daniele Pala
, et al.
·
Journal of Chemical Information and Modeling
·
15
PDF
Mechanistic Modeling of Monoglyceride Lipase Covalent Modification Elucidates the Role of Leaving Group Expulsion and Discriminates Inhibitors with High and Low Potency
2022
·
Francesca Galvani
, Laura Scalvini
, et al.
·
Journal of Chemical Information and Modeling
·
14
PDF
Development of Epigenetic Modifiers with Therapeutic Potential in FMS-Related Tyrosine Kinase 3/Internal Tandem Duplication (FLT3/ITD) Acute Myeloid Leukemia and Other Blood Malignancies
2024
·
Gabriele Carullo
, Sara Rossi
, et al.
·
ACS Pharmacology & Translational Science
·
10
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach
2023
·
Francesca Romana Ferrari
, Carmine Giorgio
, et al.
·
Biochemical Pharmacology
·
10
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity
2023
·
Lorenzo Guidetti
, Alfonso Zappia
, et al.
·
Journal of Chemical Information and Modeling
·
8
PDF
Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice
2026
·
Alex Mabou Tagne
, Faizy Ahmed
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
6
JAK3 Inhibitors: Covalent and Noncovalent Interactions of a Cyanamide Group Investigated by Multiscale Free-Energy Simulations
2025
·
Laura Scalvini
, Daniele Pala
, et al.
·
Journal of Chemical Information and Modeling
·
2
Antinociceptive interaction of Δ9-tetrahydrocannabinol and cannabidiol in a humanized mouse model of sickle cell disease
2026
·
Alex Mabou Tagne
, Olufunke Florence Ajeigbe
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
Iso‐ and Benzisothiazolinone Inhibitors of Monoacylglycerol Lipase: Exploring On‐Target Activity Through Scaffold Decoration and In Situ Warhead Generation
2026
·
Edoardo Rocca
, Annalida Bedini
, et al.
·
ChemMedChem
PDF
N-Acylaminoethyltetrahydroquinolines: A new class of melatonin receptor ligands with in vivo activity on glioblastoma
2025
·
Annalida Bedini
, Francesca Galvani
, et al.
·
European Journal of Medicinal Chemistry
Show more works
View as search
Works count:
15
Citation count:
172
H-index:
9
I10-index:
9
Year
Topic
Type